---
title: "UnitedHealth Group (UNH) Financial Research Report · Feb 19, 2026 (2)"
author: "DeepValues Research"
publisher: "DeepValues Research (DeepValues / LuLu Ventures LLC)"
type: "Research article"
ticker: "UNH"
company: "United HealthCare"
sector: "Healthcare"
industry: "Healthcare Plans"
wikidata: "https://www.wikidata.org/wiki/Q2103926"
wikipedia: "https://en.wikipedia.org/wiki/UnitedHealth_Group"
date: "2026-02-19"
language: "en"
section: "Company Research"
answer: "DeepValues Research published “UnitedHealth Group (UNH) Financial Research Report” on United HealthCare (UNH) on Feb 19, 2026. UnitedHealth Group's latest earnings (Q3 2025) showed revenue growth but significantly lower profit margins due to higher medical costs."
canonical_url: "https://research.deepvalues.ai/company/unh/unitedhealth-group-unh-financial-research-report/"
markdown_url: "https://research.deepvalues.ai/company/unh/unitedhealth-group-unh-financial-research-report/index.md"
license: "CC BY 4.0"
license_url: "https://creativecommons.org/licenses/by/4.0/"
cite_as: "DeepValues Research, UnitedHealth Group (UNH) Financial Research Report · Feb 19, 2026 (2), https://research.deepvalues.ai/company/unh/unitedhealth-group-unh-financial-research-report/"
publisher_url: "https://deepvalues.ai"
app: "https://deepvalues.ai"
api: "https://app.deepvalues.ai/developers"
data_note: "Reports are dated snapshots. Current data via the DeepValues API: https://app.deepvalues.ai/developers"
disclaimer: "Educational research, not investment advice."
---
# **UnitedHealth Group (UNH) Financial Research Report**

**Disclaimer:** This content reflects the views of the author(s) as of the date indicated and is for educational and informational purposes only. It is not investment advice. Do your own due diligence with a licensed financial advisor before making any investment decisions.

## **Latest Quarter Earnings Summary**

UnitedHealth Group's latest earnings (Q3 2025) showed **revenue growth but significantly lower profit margins** due to higher medical costs. **Revenue rose 12%** year-over-year to **$113.2 billion** , driven by growth in Medicare Advantage and Medicaid enrollment. UnitedHealthcare, the insurance division, saw **revenues up 16% to $87.1 billion** , adding \~795,000 more consumers year-over-year (total \~50.1 million in the U.S.) . Optum (health services division) grew revenue 8% to $69.2 billion , led by Optum Rx pharmacy services.

However, **profitability declined sharply.** Q3 2025 **operating earnings** were **$4.3 billion**, down 50% from $8.7 billion in Q3 2024 . The consolidated **net profit margin fell to 2.1%** (vs 6.0% a year ago) . Net income was about **$2.35 billion**(≈$2.59 GAAP EPS), roughly one-third of the $6+ billion earned in Q3 2024 . This margin compression was primarily due to **elevated medical costs**: the medical care ratio jumped \~4.7 percentage points to **89.9%** as seniors caught up on delayed surgeries and new Medicare funding cuts took effect . Both UnitedHealthcare and Optum Health saw significantly lower operating profits. For example, UnitedHealthcare's operating margin dropped to 2.1% (from 5.6%) , and Optum Health's earnings fell sharply (Q3 operating profit was only $255 million vs $2.16 billion prior year) .

Despite the earnings drop, management noted these cost pressures were anticipated and **raised the full-year 2025 EPS outlook** slightly (to at least $14.90 GAAP EPS) , signaling optimism for improvement. They emphasized "solid execution" and positioning for a return to **"durable growth in 2026"** . Indeed, cash flows remained strong - Q3 operating cash flow was **$5.9 billion (≈2.3× net income)** , indicating robust underlying cash generation. In summary, Q3 2025 showed **continued top-line growth** across businesses but **temporarily depressed margins** due to higher care costs, a situation management expects to stabilize going forward.

## **Business Model**

**UnitedHealth Group's business model is a diversified mix of health insurance and health services.** The company operates two major platforms: **UnitedHealthcare**, which provides insurance benefits, and **Optum**, which offers healthcare services, pharmacy benefits, and data/analytics solutions . UnitedHealthcare generates the majority of revenue through **insurance premiums**, while Optum earns fees from healthcare services, prescription drug benefits, technology, and consulting. This dual-platform structure gives UnitedHealth multiple income streams and a vertically integrated model (insuring patients and also providing care and services).

### **Revenue Streams & Sources of Income**

UnitedHealth's main revenue sources are:

-   **Premiums (保险保费收入):** Premiums collected from employer plans, Medicare Advantage, Medicaid, and other insurance products account for roughly **75-80% of total revenue** . In 2023, premium revenue was $290.8 billion (78% of $372 billion total) . This reflects UnitedHealthcare's core insurance business.

-   **Products (医药产品销售):** Sales of medical products and pharmaceuticals (largely through Optum Rx pharmacy benefit management) contribute about **10-12% of revenue** . For 2023, product revenue was $42.6 billion (11% of total) . This includes mail-order prescriptions, medical devices, and other health products.

-   **Services (医疗服务收入):** Fees from healthcare services, consulting, and technology (Optum Health clinics, Optum Insight analytics) make up roughly **8-10% of revenue** . In 2023, services revenue was $34.1 billion (9% of total) . Examples are payments for managing clinical care, performing data analysis for providers, or administering benefits.

-   **Investment & Other Income:** The company also earns a small portion (\~1-2%) from investment income on its large insurance float and other miscellaneous sources . In 2023 this was $4.1 billion (about 1% of total revenue) .

These sources are illustrated in the 2023 revenue breakdown below:

*2023 Revenue by Source: \~78% from insurance premiums, \~11% from products (pharmacy sales), \~9% from services, \~1% other.*

Notably, UnitedHealthcare's insurance operations dwarf the others in revenue - in 2024 UnitedHealthcare had $298 billion in revenue versus Optum's $253 billion (before eliminating internal transfers). **Premiums are the lifeblood of the company's top line** , essentially pooling customer payments to cover healthcare claims. The Optum divisions, while smaller in revenue, are high-growth and strategic, providing diversification. For example, Optum Rx manages over 1.6 billion annual prescription scripts , and Optum Health delivers care (clinics, surgery centers, etc.) for 4.7 million patients in value-based arrangements .

### **Customer Base and Unit Volume**

UnitedHealth serves **over 150 million unique individuals worldwide** through its various products . This includes \~50 million Americans enrolled in UnitedHealthcare medical benefit plans , and millions more served through Optum services (such as pharmacy or care delivery). By Q3 2025, UnitedHealthcare's domestic medical membership reached **50.1 million** people across employer plans, Medicare, Medicaid, and individual markets. Additionally, UnitedHealthcare's global division covers \~2.2 million people internationally .

Optum's customer reach overlaps but is also extensive. Optum Health, for instance, served **96 million consumers** in Q3 2025 across its clinics, digital health, and financial services (like health savings accounts) . Optum Rx, as a pharmacy benefits manager, handles prescriptions for tens of millions of patients (1.62 billion adjusted prescriptions in 2024) . **In total, UnitedHealth's services touch roughly 1 in 2 Americans** when considering all insurance members, pharmacy patients, and care service users - giving it unparalleled scale.

In terms of "units" sold: for insurance, the "unit" is a member-month of coverage - UnitedHealthcare logs billions of member-months per year. For Optum Rx, a key volume metric is **prescription scripts** (over **1.6 billion annually** in 2024 ). Optum Health tracks patients under care (4.7 million in value-based care in 2024 ), and Optum Insight tracks contract backlog ($32.1 billion at Q3 2025) . These volume measures all show robust growth trends (e.g. UnitedHealthcare added 2.1 million net new members in 2024 , Optum Rx's script volumes grew 16% YoY in Q3 2025 ).

### **Competitive Moat**

UnitedHealth Group's **moat (竞争优势)** is considered one of the strongest in healthcare. Key elements include:

-   **Unmatched Scale & Network Effects:** UnitedHealthcare is the largest U.S. health insurer, giving it huge bargaining power with hospitals and drugmakers. Its vast membership (50M+) attracts providers, and its provider networks in turn attract more customers - a self-reinforcing network effect that new entrants struggle to replicate. Its Optum Rx unit is also one of the top pharmacy benefit managers, leveraging massive volume to secure rebates on drugs .

-   **Diversification & Vertical Integration:** By combining insurance (payer) and services (provider) under one roof, UnitedHealth can offer integrated solutions competitors cannot easily match. **Optum's capabilities (clinics, data analytics, PBM)** differentiate UNH's offerings and create cross-selling opportunities . This vertical integration can improve care coordination and cost control (a patient's insurance, pharmacy, and care may all be managed by UHG), which is hard for stand-alone insurers or providers to emulate.

-   **Data & Technology:** With *data on over 147 million individuals* and advanced analytics (Optum Insight), UHG has proprietary insights into healthcare utilization. This helps in pricing risk accurately, managing population health, and creating tech-driven services (e.g. AI-driven clinical decision support) . The company invests heavily in technology (nearly $3-4 billion in annual D&A on IT and infrastructure ) to maintain this edge.

-   **Regulatory Expertise & Capital:** Operating in complex regulated markets (Medicare, Medicaid) requires deep expertise. UnitedHealth has decades of relationships with government payers and compliance infrastructure that form a barrier to entry. Its strong balance sheet (over $100 billion equity) and cash flows (> $25 billion FCF annually in recent years) allow it to continuously invest, acquire competitors (e.g. $13B acquisition of Change Healthcare in 2022), and weather industry challenges that smaller players could not.

-   **Brand and Trust:** UnitedHealthcare and Optum are well-known brands. UnitedHealthcare often ranks first or second in market share in its major segments (e.g. largest Medicare Advantage insurer, major employer insurance carrier). While health insurers aren't always beloved, scale and reputation do influence large corporate and government clients when choosing administrators.

These moats have translated into **consistent growth and high returns**. Over the past decade, UHG compounded revenue \~12% annually and net income \~15% annually , while averaging \~20-25% return on equity . This track record and multifaceted moat help insulate UnitedHealth from competitive threats, including upstart insurers, healthcare disruptors, or potential new entrants (few can match UHG's breadth of offerings and cost advantages).

## **Headwinds & Risks**

UnitedHealth Group faces a variety of **short-term headwinds** as well as **longer-term risks** that could impact its business:

### **Short-Term / Temporary Factors**

-   **Medical Cost Surges:** As seen in 2023-2025, pent-up demand for care (e.g. post-pandemic elective surgeries) can temporarily drive medical costs above expectations . In mid-2023, UnitedHealth warned of a spike in seniors getting hip and knee surgeries, which raised its medical loss ratio and rattled investors . Such cyclical utilization surges (often following suppressed periods) are short-term headwinds that pressure margins until utilization normalizes.

-   **Regulatory Rate Adjustments:** Government programs are subject to annual funding changes. For instance, **Medicare Advantage reimbursement rates** for 2024 were reduced (and risk adjustment rules tightened), squeezing margins in that year . UnitedHealth's Q3 2025 results indicate this ("Biden-era Medicare funding reductions…Part D changes") as a drag on earnings . However, these rate cuts tend to be incremental; UNH can often adjust benefits/premiums or see offsets in subsequent years. Nonetheless, in the short run, new rules (e.g. **Inflation Reduction Act** drug pricing caps) can create earnings headwinds until mitigated .

-   **Political Pressure & Public Scrutiny:** Periodic public controversies can create near-term turmoil. For example, in 2023, UnitedHealth faced scrutiny over its **prior authorization practices** (delays/denials of care). Shareholders even filed a proxy proposal to report on the public health impacts of these policies . Although that proposal was withdrawn, the publicity (Congressional and media attention) was a short-term reputational headwind. Similarly, high healthcare premiums during inflationary periods can bring political heat (threats of regulation or premium caps), which may weigh on sentiment temporarily.

-   **Pandemic/Epidemic Volatility:** Short-term shocks like COVID-19 illustrate how external events swing costs. In 2020, UnitedHealth's profits jumped as care utilization dropped (MCR fell when hospitals postponed procedures) , but then in 2021 costs rebounded. New virus outbreaks or health crises can create volatile quarterly results (with either unexpected cost or deferred care patterns). These effects tend to even out over several quarters as the system adjusts, but cause short-term earnings noise.

-   **Integration of Acquisitions:** After large acquisitions (like the recent $5.4B buyout of Amedisys home health in Aug 2025 ), UnitedHealth may face a few quarters of integration costs and learning curve. For example, OptumHealth's profit was depressed in 2023-2024 partly as it integrated recently acquired physician groups . These are temporary drags - if integrations proceed well, performance improves thereafter.

In summary, short-term headwinds often relate to **cost trend surprises, policy tweaks, or one-time events**. UnitedHealth has generally navigated these by adjusting pricing, deploying capital, or simply riding out the volatility given its strong capital position.

### **Long-Term / Structural Risks**

-   **Healthcare Policy & Reform:** Perhaps the largest long-term threat is **major U.S. healthcare reform** that reduces the role of private insurers. A "Medicare for All" single-payer system (periodically debated in Washington) could drastically shrink UnitedHealth's insurance business if ever enacted . While full single-payer has low political odds in the near future, incremental reforms could still impact UHG - e.g. a government public option plan competing in the employer market, or expanded Medicare that erodes Medicare Advantage enrollment. UnitedHealth mitigates this by participating in government programs (it's deeply involved in Medicare/Medicaid administration ), but the **political risk of healthcare policy shifts** remains a long-term factor.

-   **Cost Containment & Regulation of Insurers:** There is sustained pressure to curb healthcare costs, and insurers like UHG often become targets. Regulations capping insurer profits (like the ACA's medical loss ratio minimums of \~85% that limit margins) are an ongoing reality . Further stringent rules - for instance, limits on premium increases, drug rebate reforms that squeeze OptumRx, or stricter oversight of insurer-provider contracts - could structurally compress margins. The company already operates on \~5-6% net margins , so any permanent squeeze on that spread (by law or competitive necessity) is a long-term risk.

-   **Changing Healthcare Delivery Models:** UnitedHealth's insurance model could be challenged if healthcare shifts to **value-based care or direct provider contracting** at scale. For example, large hospital systems or tech companies might contract directly with employers, cutting out traditional insurers, or new care models (telehealth, at-home primary care) might lower the value of broad networks. UnitedHealth is countering this by moving into care delivery itself (OptumHealth's clinics, etc.) and by offering its own value-based products . But the risk is that the classic insurer role could be partially disintermediated in the long run by more integrated provider systems or government payers.

-   **Competition from Tech Entrants:** Big technology firms (Amazon, Google, Apple) have shown interest in healthcare. Amazon acquired a primary care chain (One Medical) and offers pharmacy services - a direct shot at parts of UHG's business. While none have the scale to threaten UHG's core yet, the long-term risk is a disruptive new model (perhaps a low-cost digital health plan or AI-driven care) eroding UnitedHealth's market share, especially if employers or consumers gravitate to new offerings. UnitedHealth's moat in data and network is significant, but tech giants' resources mean this risk can't be ignored.

-   **Demographics & Utilization Trends:** An aging population is a double-edged sword - it expands UnitedHealthcare's Medicare membership (opportunity) but also means higher average costs per member. Over decades, if healthcare advances cause people to live longer with expensive chronic conditions, insurers could face rising cost burdens that outpace premium increases. UnitedHealth's long-term sustainability relies on managing cost trends (through care management, preventive care) - if industry medical cost growth consistently exceeds economic growth, margins could be pressured long-term unless premiums rise (which invites regulatory pushback).

-   **Legal and Compliance Risks:** UnitedHealth has faced and could face **large-scale litigation or regulatory action**. For example, the DOJ has an ongoing probe into Medicare Advantage risk adjustment practices (potential overcoding of patient diagnoses to increase payments) . A major adverse legal judgment or settlement (e.g. a finding of fraud in coding) could not only cost billions in fines but force changes in practices that permanently reduce revenue (by coding more conservatively). Additionally, UnitedHealth must comply with privacy/security laws - a severe data breach of health records (like the 2023 cyberattack affecting \~100 million records via Optum's Change Healthcare unit ) can impose long-term reputational and financial damage. Maintaining robust compliance is a perpetual risk mitigation area.

In summary, **permanent risks revolve around systemic changes** - whether political (single-payer), competitive (new models/entrants), or structural (population health and legal constraints). UnitedHealth's strategy has been to **diversify and integrate** to cushion against these (for instance, if insurance margins compress, Optum's service profits can compensate). Nonetheless, investors must monitor these long-run issues as they determine the industry's trajectory and UnitedHealth's role in it.

## **Cost Structure**

UnitedHealth Group's cost structure comprises **variable costs tied to medical claims and services, and fixed costs like administrative overhead**. Understanding its expenses is key to evaluating profitability:

-   **Medical Claims (Variable Cost per Member):** By far the largest cost is **medical claims expense** - what UnitedHealthcare pays for members' hospital bills, doctor visits, prescriptions, etc. This is **variable** with enrollment and healthcare utilization. In 2023, "medical costs" were $241.9 billion , about 65% of total revenue (and \~82.0% of premium revenue, i.e. the medical care ratio ). On a per-unit basis, UnitedHealthcare's U.S. commercial members incur roughly $5,000-$6,000 in medical cost annually (higher for seniors). If utilization rises (as in 2023's post-COVID surge), these variable costs increase. Medical cost per member can also rise with inflation (hospital prices, drug prices). UnitedHealth's scale helps negotiate lower unit prices than smaller insurers - a crucial advantage in controlling per-unit cost.

-   **Pharmacy & Product Costs (Variable):** For Optum Rx and other product revenues, **cost of goods sold** includes payments to drug manufacturers and suppliers. In 2023, "cost of products sold" was $38.8 billion , implying roughly 91% of product revenue (42.6B) went to procuring drugs/devices, a slim gross margin business. These costs vary with prescription volume and drug prices. As a PBM, Optum Rx typically retains a small spread or rebate on drugs - so drug cost inflation generally passes through (with a lag) to higher revenues, keeping Optum's dollar margin per script relatively stable. However, any inability to secure rebates (a risk if drug pricing reforms curtail PBM rebates) could narrow this spread.

-   **Employee Compensation (Semi-variable):** UnitedHealth is a massive employer (\~380,000 employees in 2025 ). **Labor costs** (salaries, benefits) are a major component of "operating costs" which were $54.6 billion in 2023 . This includes thousands of clinicians in OptumHealth clinics, call center staff, claims processors, IT engineers, etc. Some of these costs scale with business volume (e.g. more nurses hired as membership grows), but there are also economies of scale. Over 2019-2024, the operating cost ratio held around 14-15% of revenue , slightly declining as revenue grew - indicating efficiency gains even as absolute labor costs rose. Nonetheless, in tight labor markets, wage inflation can pressure margins. For example, if nurse salaries rise 5% in a year, UnitedHealth's clinic costs increase accordingly (though it may attempt to offset via productivity improvements or technology).

-   **Technology & Amortization (Fixed/Stepped):** UnitedHealth invests heavily in IT systems (claims adjudication platforms, data analytics, digital health apps). Depreciation and amortization was $4.0 billion in 2023 . Much of this is relatively fixed in the short term - the company has to spend on infrastructure regardless of whether membership grows 2% or 5%. Similarly, facilities costs (office leases, data centers) are fixed. These create high operating leverage: once built, the systems can handle more volume with little incremental cost. This is why growing membership tends to improve UHG's administrative cost ratio over time (spreading fixed IT costs across a larger base).

-   **Marketing & Acquisition Costs (Semi-variable):** To acquire members, especially in Medicare's Annual Enrollment Period, UnitedHealth incurs significant **marketing and broker commission expenses**. These are part of SG&A (selling, general & administrative). They can vary year-to-year - e.g. aggressive marketing drives higher sign-ups but at a cost. In Medicare Advantage, brokers are paid fixed fees per enrollment regulated by CMS. UnitedHealth's marketing spend is not explicitly broken out, but the stable operating cost ratio \~14-15% suggests it manages these expenses in line with revenue. In economic downturns, marketing might be cut as a lever to protect margins; conversely, ahead of growth opportunities (new markets), UHG might temporarily spend more.

-   **Most Significant Costs:** The dominant cost is **medical claims**. This alone represented **$0.83 of every $1** of premium in 2023 . Next significant are operating/admin costs ($0.15 per $1 of revenue) which includes salaries, marketing, etc. . Product costs (for pharmacy) also substantial in absolute terms but confined to Optum's segment. Interest expense was $3.25 billion in 2023 , much smaller relative to operating costs. So in hierarchy: medical > admin/labor > product costs > depreciation > interest.

-   **Cost Behavior Over Time:** UnitedHealth has generally **improved cost efficiency over time**. The operating cost ratio fell from \~16% in 2014 to \~13% in 2024 , thanks to automation and scale (for instance, digital claim processing reduced manual work). In boom times or inflationary periods, admin costs may tick up (e.g. labor shortages in 2022 raised wage costs). Economic conditions also impact medical costs: in recessions, utilization can dip as people postpone care (helping insurers' short-term profits), whereas in strong economies more elective care is consumed. UnitedHealth's costs thus partially correlate with the economic cycle of healthcare utilization. Nevertheless, secularly, UHG has kept cost trend slightly below revenue trend, enabling margin expansion. The **risk** is if external cost growth (drug prices, hospital rates) consistently outpaces premium growth - insurers then either raise premiums (limited by competition/regulation) or eat the margin impact. UnitedHealth leverages multi-year provider contracts and its Optum capabilities (manage care in-house) to control this, and historically has navigated different conditions (even in high inflation 2022-2023, UHG maintained margins by pricing ahead and efficiency gains ).

In summary, **variable medical costs dominate** UHG's P&L, making medical trend management crucial. Fixed costs provide leverage (driving profit growth when revenues rise faster than admin costs). UnitedHealth's scale and diversification give it cost advantages - spreading fixed costs and negotiating volume discounts - that have kept its cost ratios relatively stable or improving over the long run.

## **Management & Governance**

UnitedHealth Group's management team and governance practices have evolved over time, but the company has generally been regarded as well-managed. Here's an overview:

### **Executive Leadership & Board**

**Current Executive Team:** As of late 2025, **Stephen J. Hemsley** is CEO (and Chairman) of UnitedHealth Group . Hemsley led UHG as CEO from 2006-2017, then returned to the chief executive role in May 2025 amid a strategic pivot . He is credited with UnitedHealth's tremendous growth in the 2000s and is known for operational discipline. The President and COO roles are held by other long-tenured executives - for instance, prior to 2025, **Dirk McMahon** was President/COO of UHG (he retired mid-2023 after 26 years at the company). The CFO is **John Rex** (since 2016), who has overseen financial strategy and capital allocation during UHG's expansion.

Supporting them, UHG's broader executive team includes CEOs of divisions: e.g. **Brian Thompson** was CEO of UnitedHealthcare until late 2024 (he tragically passed away in Dec 2024) ; **Wyatt Decker, MD** leads OptumHealth; **Heather Cianfrocco** leads OptumRx; and **Eric Murphy** OptumInsight - all seasoned leaders in their domains.

**Board of Directors:** The board is composed of 10 members (8 independent) with diverse backgrounds . Lead Independent Director is **Michele Hooper**, an experienced corporate director who ensures independent oversight . The board includes healthcare experts (e.g. **Richard Migliori, MD** - UHG's former Chief Medical Officer), financial experts (e.g. **Timothy Flynn**, ex-chair of KPMG ), and public policy leaders (**Charlie Baker**, former Governor of Massachusetts, joined in 2023 ). Notably, company founder **Richard T. Burke** (who founded UHG in 1977) served on the board for decades but is now retired (he holds the honorary title of Chairman Emeritus). The board separates the Chairman and CEO roles in principle, though Hemsley as Executive Chair currently holds both titles combined (with a Lead Director in place) . Overall, the board has been refreshed significantly in recent years - five new directors since 2019 - to bring new perspectives .

**Historical Executives:** UnitedHealth's leadership bench has been relatively deep. Hemsley's first tenure succeeded **Dr. William McGuire**, the long-time CEO (1990s-2006) who built UHG but resigned amid a stock option backdating scandal in 2006. After Hemsley, **David Wichmann** was CEO (2017-2021), followed by **Sir Andrew Witty** (2021-2025). Witty was a former GlaxoSmithKline CEO who focused UHG on innovation but stepped down in 2025 for personal reasons . Many executives are company veterans - e.g. McMahon, Rex, etc., have been with UHG for decades - providing continuity in culture.

**Founder/Long-Time Influence:** While founder Richard Burke no longer has an active role, both he and Hemsley (a near-founder in tenure, joined 1997) shaped the culture. Hemsley's return signals a "back to basics" approach to execution . Investors have generally welcomed having his experienced hand during the recent cost challenges .

### **Management Track Record & Integrity**

**Strategic Execution:** UnitedHealth's management has a strong track record of meeting or exceeding financial targets over the past 20+ years. They have consistently grown EPS and typically provide conservative guidance then deliver slight beats . For example, under Hemsley's prior leadership, UHG navigated the implementation of the ACA smoothly and hit its goal of 13-16% long-term earnings growth . The current team similarly raised full-year 2025 outlook even in a challenging environment , indicating confidence in hitting promised numbers.

**Follow-Through:** Management generally follows through on stated initiatives. In 2019, they outlined a strategy to *double Optum's earnings* within 5 years - and indeed, Optum's operating earnings rose from $8.1B in 2018 to \~$16.7B in 2024 . When issues arise, they address them openly: in mid-2023 when medical cost trends spiked, then-CEO Witty did not hide the problem - he explicitly alerted investors on the Q2 call that trends were above baseline, even though it meant suspending guidance temporarily . This transparency was uncomfortable but showed a willingness to confront problems rather than obscure them.

**Transparency & Trust:** Historically, one black mark was the 2006 stock option scandal where Dr. McGuire backdated options - UHG had to restate earnings and pay fines. Since then, governance controls improved and no major financial reporting issues have occurred. The company provides detailed segment disclosures and metrics (e.g. medical cost reserve development, days claims payable) that many peers do not, suggesting a culture of disclosure. However, there are criticisms: e.g. some say UHG (like others) could be more transparent about Optum's internal transactions with UHC. Also, the ongoing DOJ inquiry into risk adjustment has raised questions whether UHG pushed too far in maximizing payments . Management asserts confidence in their coding integrity , but a negative finding could imply prior practices were aggressive. That said, thus far no executives have been implicated in wrongdoing; it appears to be an industry-wide issue.

**Analyst Engagement:** On earnings calls, UHG's management is generally candid and knowledgeable. Analysts often praise their depth of data. For instance, analysts pressed Witty and Hemsley on the elevated medical trends; management provided granular detail (surgical categories driving it, etc.) and their mitigation plans, rather than evasive answers . The tone is usually one of long-term focus rather than short-term excuses. Management's willingness to adjust guidance mid-year (as in 2025) rather than deny reality also earned some credibility back with investors .

**Tenure & Stability:** Many of UHG's top leaders have very long tenures (often 20+ years). This stability has helped maintain a consistent strategic direction. There have been some planned transitions - e.g. Witty's departure was unexpected, but having Hemsley step back in provided instant continuity . The bench is strong; even after Hemsley's eventual final retirement, potential successors include Optum head CEO Andrew Witty (if he returns from advisory role) or others groomed internally. Longevity also means these leaders deeply know the business operations.

**Integrity Questions:** Aside from the mid-2000s options issue (which was resolved by leadership change and substantial pay givebacks by McGuire ), there haven't been major integrity scandals attributed to current management. Some healthcare providers accuse all insurers of being difficult (e.g. refusing claims); UnitedHealth specifically has faced lawsuits over mental health claim denials (settled in 2019) and was fined for certain claims practices . These reflect the tension inherent in the insurance role. Importantly, no recent accusations suggest management is hiding financial problems - UHG's financials are regarded as high quality (the company even voluntarily held excess reserves during the pandemic to be prudent). However, given the size, it's always possible that issues in one of thousands of operations could emerge (like a regulatory fine in a subsidiary). Overall, management is viewed as **competent and ethical by industry standards**, balancing obligations to customers and shareholders.

### **Management Incentives & Shareholder Alignment**

**Insider Ownership:** UnitedHealth's executives and directors do hold meaningful equity stakes, aligning their interests with shareholders. Notably, CEO Stephen Hemsley owns over **1.1 million UNH shares** (worth \~$400 million) . He actually increased his stake upon returning - in May 2025, Hemsley bought \~$25 million of UNH stock on the open market at \~$289/share , a strong signal of confidence and alignment. Other top executives receive much of their compensation in stock and are subject to stock ownership guidelines (executives must hold a multiple of their salary in shares) . As of April 2024, all execs and directors met these ownership requirements .

**Compensation Structure:** Management's pay is tied to performance metrics. The annual incentive and long-term equity awards are based on earnings, growth, and return on equity targets . For example, bonuses depend on hitting EPS and revenue goals, and PSU (performance stock units) vest based on multi-year EPS growth and ROE. This incentivizes leaders to focus on profitable growth. In 2023, 96% of shareholder votes supported UHG's executive compensation program , reflecting shareholder approval of the pay-for-performance alignment.

**Capital Allocation & Skin in the Game:** Management has demonstrated shareholder-friendly capital allocation - returning cash via buybacks and dividends while investing in growth. They **reinvest earnings primarily in the business or share repurchases**. The dividend, while growing (from $0.03/share in 2010 to $7.52 in 2025 annually), is kept moderate (payout \~30% of net income) , so a large portion of earnings are retained for growth or buybacks. Executives benefit from share price appreciation more than outsized cash salaries, which aligns them with long-term stock performance. Indeed, Hemsley's wealth is largely tied to UNH stock value - as noted, he bought on dips (e.g. during 2025's share price decline) . This signals he personally believes growing the business will yield more reward than any short-term actions to boost his cash pay.

**History of Actions in Downturns:** During short-term stock declines, insiders have sometimes been buyers. In addition to Hemsley's 2025 buy, insider reports show few large discretionary sales - most sales are part of 10b5-1 plans. This suggests management is not cashing out opportunistically; they stay invested. Also, the board has authorized substantial share repurchases when the stock is under pressure (e.g. new buyback authorizations in 2022-2024 when the stock dipped) , indicating management's confidence in the intrinsic value and desire to return capital to shareholders at attractive prices.

**Reputation and Accountability:** No significant questions of integrity have been raised about current management's honesty with investors. On the contrary, CEO Hemsley is often described as **laser-focused and candid**, even nicknamed a "ninja" operator by analysts for his ability to quietly improve operations . The company's governance includes clawback policies for executive compensation in case of misconduct or restatement , discouraging any temptation to juice results improperly.

In summary, **UnitedHealth's management is experienced, shareholder-aligned, and has a strong execution record**. They have navigated industry changes effectively and generally treat shareholders as partners - evidenced by open communication, significant insider ownership, and consistent capital returns. This has earned management a solid reputation on Wall Street, although ongoing vigilance is needed (particularly regarding regulatory compliance and maintaining alignment as the company grows ever larger).

## **Shareholders & Capital Returns**

UnitedHealth Group's shareholder base is dominated by large institutional investors, and the company has an active capital return program (dividends and buybacks). Here we cover the major shareholders, their engagement, and UHG's capital allocation history:

### **Top Shareholders & Voting Influence**

**Institutional Ownership:** About **90% of UNH shares are held by institutions** . The top three holders are **The Vanguard Group (\~10% stake)**, **BlackRock (\~8%)**, and **State Street (\~5%)**, which together own \~23% . These are passive index giants that generally support management on votes. For example, in 2024's say-on-pay vote, \~96% of votes cast were in favor - indicating Vanguard, BlackRock, etc., voted with the board's recommendation (they typically do unless there's a glaring issue).

Other notable institutional holders include mutual fund companies like Fidelity and Capital Group, each with \~2-3% stakes. **Berkshire Hathaway** also emerged as a significant holder - in Q2 2025, Berkshire bought \~5.04 million UNH shares (\~0.6% of shares) , a position worth \~$1.6 billion . This was seen as a vote of confidence by famed value investor Warren Buffett. Berkshire is not activist, but its presence underscores that long-term oriented investors find UNH attractive at the right price.

**Shareholder Proposals & Votes:** Major shareholders have occasionally pushed governance or social proposals. In recent years, proposals have focused on political lobbying disclosure and health equity. For instance, at the 2024 AGM a shareholder proposal requested a report on political contributions congruence; the board opposed it and likely big holders sided with the board (such proposals at peers usually get <40% support) . Another example: the **Interfaith Center on Corporate Responsibility (ICCR)**, a coalition of faith-based investors (with some UNH shares), filed a 2025 proposal urging a report on how prior authorization may harm patients . UnitedHealth sought SEC permission to omit it (no-action letter) and engaged with the filers - ultimately they withdrew it, preferring to continue dialogue off-ballot . This suggests management can constructively address investor concerns to avoid contentious votes.

**Voting Tendencies:** The large index funds (Vanguard, BlackRock) have published general voting policies supporting board recommendations in most cases but also pushing for disclosure on climate and diversity. At UHG, they have not revolted on any major item recently. Executive compensation and director elections have passed easily (>95% votes) . BlackRock did vote for a climate lobbying report proposal at another insurer, but at UNH such proposals haven't gained majority. **Proxy advisors** like ISS have largely given UHG favorable recommendations, which influences how some institutions vote. The board is well regarded (independent majority, diverse, no staggered terms, proxy access in place), so there hasn't been activist pressure for changes in governance.

One big vote where institutions would matter is in a **merger or acquisition scenario**. For example, if UHG attempted a huge merger requiring shareholder approval, top holders' support would be crucial. In UHG's own proxy fights, none notable in recent years - no activist has tried to break up UHG or such. The **only "activist" actions** have been those social proposals (like ICCR's) which have not reached a binding vote or majority.

In summary, **top shareholders are primarily passive funds** who generally support management, while a few socially-focused investors push proposals that sometimes lead to company commitments (e.g. enhanced ESG disclosures) in exchange for withdrawal. No major holder is agitating for radical changes; they appear satisfied with UHG's performance and governance.

### **Share Buyback Program**

UnitedHealth has a **robust share repurchase program** as a key component of capital return.

-   **Current Authorization:** In June 2024, the board authorized the repurchase of up to **35 million shares** of common stock . This was an expansion of the existing program. At \~$500 per share in mid-2024, that equated to \~$17.5 billion of potential buybacks. As of the latest filings, significant capacity remained for additional repurchases.

-   **Recent Activity:** UHG buys back shares opportunistically. During 2024, it repurchased about **$7.3 billion worth (14 million shares)** between April 2022 and Feb 2024 . In 2023, buybacks slowed as the company used cash for the Change Healthcare acquisition. But they accelerated repurchases in late 2024 and 2025 when the stock price fell. Notably, after suspending guidance in May 2025, UHG's stock dropped \~15%; management likely viewed this as undervalued and stepped up buybacks. By Q3 2025, the share count was \~910 million, down from \~951 million at end of 2016 - a \~4% reduction over 9 years. While this net reduction seems small, it's because new shares from employee compensation partly offset buybacks. Gross repurchases have actually been much larger: UHG spent over **$50 billion on buybacks** in the past decade, but shares outstanding only fell modestly due to stock-based compensation and acquisitions paid in stock.

-   **10-Year Comparison:** Over the last 10 years, **share count peaked around 1.01 billion in 2013 and is about 920 million in 2025** . That \~9% reduction reflects consistent buybacks. For example, in 2017-2019, UHG repurchased \~$8-10 billion per year, taking advantage of strong cash flows. In the 2010s, the board often authorized large programs (e.g. a 100 million share authorization in 2014). However, UHG also issued shares for deals (like Catamaran in 2015 partially in stock). On net, **the buyback trend has been to offset dilution and gradually reduce float**.

Looking at history: in 2015, shares were \~954M; by 2020, \~933M; by 2024, \~922M. The reduction accelerated in 2021-2022 when earnings were high and the stock at times underpriced relative to growth (e.g. $6 billion bought in 2021, $5 billion in 2022). The chart below shows year-end market cap changes, reflecting combined effects of buybacks and price movement:

*UNH Market Capitalization History:* *Share buybacks helped drive a 10× increase in market cap from 2010-2021. In 2022-2024, market cap stayed \~$470-490B as price plateaued and buybacks offset new shares.*

-   **Capital Return Philosophy:** Management targets a **40-50% payout of earnings to shareholders** via dividends and buybacks combined . In 2024, for example, UHG returned over **$16 billion** ($5.5B in dividends, \~$10.5B in buybacks) which was \~66% of that year's net income . They prioritize maintaining a **AA- credit rating**, so they balance uses of cash (reinvesting in acquisitions vs. buybacks). Generally, after funding business needs and M&A, remaining cash goes to repurchases. The fact that buyback spend often rises when the stock dips (and is tempered when the stock is higher or cash is needed for acquisitions) suggests an opportunistic approach - effectively **buying low**.

-   **Impact vs. Past:** Compared to 10 years ago, the current buyback pace is higher in absolute dollars but the effect on share count is smaller (because the market cap is much larger now). In the mid-2010s, UHG could reduce share count \~2-3% per year. More recently, it's been \~1% or less per year because the company also funds large acquisitions. Still, over a decade, even a \~10% reduction in shares outstanding has provided a nice tailwind to EPS growth (all else equal).

-   **Investor Reception:** Shareholders generally approve of UHG's buybacks, evidenced by lack of pushback and the positive effect on EPS. There was a derivative suit in 2025 alleging that UHG overpaid for shares between 2022-2024 while allegedly knowing about the DOJ investigation (arguing stock was "artificially inflated") - but this seems like an opportunistic lawsuit with little traction. The vast majority of investors prefer UHG return excess cash via repurchases, as it has done.

In conclusion, **UnitedHealth's capital return strategy has been steady dividend growth plus flexible buybacks**, accelerating when value is compelling. The current buyback authorization is ample, and we can expect UHG to continue repurchasing shares as a way to deploy its strong cash flows for shareholder benefit, just as it has over the last decade.

### **Shareholder Trading - Value Investors' Moves**

UnitedHealth's stock has attracted many long-term "value" oriented investors, and analyzing their trading can provide insight:

-   **Berkshire Hathaway (Warren Buffett):** Buffett's Berkshire initiated a stake of \~5 million UNH shares in Q2 2025 , with an estimated average cost around $275-$300 (the stock's trading range that quarter). This was a *secret buy*(Buffett used confidential filing for a period) and became public in August 2025, causing the stock to pop \~12% on the news . Berkshire's cost basis likely \~$1.5 billion (≈$300/share). As of now, they are still holding 5+ million shares (about 0.5% of the portfolio) . Berkshire is known to hold for the long term - likely they saw UNH's mid-2025 dip as a chance to own a great company at a discount. Buffett's *value discipline* (they seek <15× earnings) was met: UNH traded near 12-14× forward earnings at the lows . **Buy price:** \~$280; Buffett hasn't sold any, indicating he believes fair value is significantly higher (he often aims for >50% gain potential). No stated sell price, but if UNH skyrocketed to say 25× earnings (unlikely soon), Berkshire might trim.

-   **Appaloosa (David Tepper):** Billionaire David Tepper made UNH a high-conviction bet in mid-2025. His hedge fund Appaloosa bought 2.28 million shares in Q2, raising its stake to 2.45 million . That was \~11.8% of his U.S. equity portfolio, the \#2 position . Tepper's average cost likely similar \~$280-$300. By Q3 2025, UNH comprised \~12% of Appaloosa's holdings, showing he's still in. Tepper is opportunistic; if UNH rebounds strongly (say into the $500s), he might take profits. But given he started the position for a turnaround play, he likely expects holding through 2026 as earnings recover (perhaps targeting $450-$500 as an exit, which would be \~50-70% up from cost). Currently, he appears to be *holding firm*.

-   **Michael Burry (Scion Asset Mgmt):** Burry (of "Big Short" fame) took a small position - 20,000 shares - in Q2 2025 and also bought call options representing 350,000 shares . This indicates he was bullish on UNH's upside. His call options likely have strike in the mid-$300s, betting the stock would rebound above that. Burry often trades shorter-term; given UNH did bounce off its lows, he may have already profited on some option positions. His average buy price on shares maybe \~$290. If his thesis played out (stock back to $350-$400), he might exit. It's unclear if he held into Q4 2025 - Scion's Q3 filing showed no common shares (possibly he sold shares and kept only options, or closed entire trade for a gain). Burry's involvement underscores that even typically bearish investors saw UNH as oversold in 2025.

-   **Other Value Investors:** A UK fund manager, **Stephen Yiu (Blue Whale Capital)**, increased his UNH stake by 35% in Q2 2025 (to \~104k shares) , showing confidence in its "significant value" at the time. **Yacktman Asset Management** (noted value-focused fund) holds \~129k shares as of 2025, having added modestly - they've likely held UNH for years given its stable growth and shareholder returns. **Chase Coleman's Tiger Global** (a growth-value crossover fund) also is listed as a holder of \~1.5 million shares , possibly viewing UNH as a reliable compounder. Their average prices vary (some might have bought earlier at higher prices), but notably none of these investors have rushed for the exits - they appear to be maintaining or adding to positions on weakness.

-   **Historical Buys/Sells:** Looking back, many value investors first bought UNH in the mid-2010s when it traded at 15× earnings ($100 stock). For instance, Berkshire had considered managed care stocks earlier (Buffett mentioned them as strong in 2017 but hadn't bought yet). By 2020, some funds trimmed as valuation climbed (\~22× earnings). When the P/E compressed in 2023-2025, they returned. We saw this in 2021: UNH was \~$400-$500 (high P/E \~22×), some value-oriented funds took profits. Then in 2023's bear market, **Dodge & Cox** (deep value fund) added UNH around $480. In mid-2025's dip to $240-$300 (P/E \~12-14×), multiple value gurus (Buffett, Tepper, Burry) piled in, with **average buy prices roughly $270-$300**.

As of late 2025, these value investors **are largely still holding**, expecting a rebound. Their thesis is likely that UNH's earnings will normalize/improve in 2026+, so the forward P/E on their buy cost might be <10. For example, Buffett may foresee $30 EPS in 2026; at his \~$280 cost that's 9.3× - a bargain for a high-quality franchise. They might sell if the stock overshoots to an expensive level (say >20× forward earnings). But given UNH's typical valuation range (15-18× historically), they likely see room for upside. In percentage terms, many of these investors would be satisfied with a \~50% gain. If UNH returns to \~$500 (near previous high) in a couple years, some will trim or exit, locking in that profit. Until then, **their holding percentages remain significant**: Berkshire \~0.6% of shares, Appaloosa \~0.27%, Tiger Global \~0.16%, etc., indicating continued confidence.

In summary, **prominent value investors bought UNH during its 2025 downturn**, at prices mostly in the high $200s. They are **holding patiently**, expecting the company's fundamentals to reassert and the stock to recover. Their average buy vs. current price (\~$370 late 2025) already reflects gains, but most are likely to hold for further upside (or until the stock reaches their intrinsic value estimates). This behavior underscores the market's view of UHG as a solid long-term compounder that occasionally offers an attractive entry when short-term fears depress the price.

## **10-Year Key Metrics (2015-2024)**

The table below presents UnitedHealth Group's key financial metrics over the past 10 years. Figures are in **USD** (billions, except per-share and ratios):

| **Year** | **Market Price** | **Book Value/Share** | **P/E** | **P/B** | **Market Cap** | **Total Assets** | **Total Liabilities** | **Book Value (Equity)** | **Cash & Equiv.** | **Revenue** | **Rev Growth** | **Gross Profit** | **Gross Margin** | **Operating Profit** | **Op Margin** | **Net Income** | **Net Inc. Growth** | **Net Margin** | **Free Cash Flow** | **FCF Margin** | **Capital Expenditures** | **Maint. CapEx** | **Owner's Earnings** | **OE Margin** | **Retained Earnings** | **RORE** | **ROIC** | **ROE** | **ROA** | **Int. Exp/Op Inc** | **Current Ratio** | **Debt/Equity** | **Debt/Assets** | **Deprec./Gross** |
|----------|------------------|----------------------|---------|---------|----------------|------------------|-----------------------|-------------------------|-------------------|-------------|----------------|------------------|------------------|----------------------|---------------|----------------|---------------------|----------------|--------------------|----------------|--------------------------|------------------|----------------------|---------------|-----------------------|----------|----------|---------|---------|---------------------|-------------------|-----------------|-----------------|-------------------|
| **2015** | $117.5           | $35.3                | 19.6×   | 3.3×    | $112B          | $111.3B          | $77.5B                | $33.7B                  | $31.7B            | $157.1B     | +20.4%         | $37.0B           | 23.6%            | $11.0B               | 7.0%          | $5.8B          | +3.4%               | 3.7%           | \~$8.2B            | 5.2%           | $1.8B                    | \~$1.8B          | \~$6.0B              | 3.8%          | $37.1B                | -        | \~13%    | 17.7%   | 5.2%    | 7.2%                | 0.8               | 0.95            | 0.70            | \~5%              |
| **2016** | $160.0           | $40.1                | 22.1×   | 4.0×    | $152B          | $122.8B          | $84.6B                | $38.2B                  | $37.1B            | $184.8B     | +17.6%         | $42.6B           | 23.1%            | $12.9B               | 7.0%          | $7.0B          | +20.7%              | 3.8%           | \~$9.5B            | 5.1%           | $2.0B                    | \~$2.0B          | \~$7.0B              | 3.8%          | $40.9B                | 15%      | \~12%    | 19.4%   | 5.7%    | 8.3%                | 0.8               | 0.86            | 0.69            | \~6%              |
| **2017** | $225.0           | $46.0                | 22.0×   | 4.9×    | $214B          | $149.5B          | $99.5B                | $50.0B                  | $38.0B            | \~$201B     | +8.8%          | $46.0B           | \~22.8%          | $14.0B               | 7.0%          | $10.6B         | +51.2%              | 5.3%           | \~$12.0B           | \~6%           | $2.2B                    | \~$2.2B          | \~$8.5B              | 4.2%          | \~$48B                | 18%      | \~13%    | 22%     | \~7.1%  | \~7.6%              | 0.9               | 0.66            | 0.67            | \~5%              |
| **2018** | $252.7           | $52.5                | 21.1×   | 4.8×    | $240B          | $155.6B          | $104.9B               | $50.7B                  | $24.5B            | $226.2B     | +12.5%         | $52.5B           | 23.2%            | $15.6B               | 6.9%          | $11.99B        | +13.1%              | 5.3%           | $13.0B             | 5.8%           | $2.4B                    | \~$2.4B          | $9.6B                | 4.2%          | \~$58B                | 14%      | \~13%    | 22.5%   | 7.7%    | 6.8%                | 1.0               | 0.72            | 0.67            | \~5%              |
| **2019** | $296.0           | $59.1                | 18.5×   | 5.0×    | $279B          | $194.2B          | $134.5B               | $59.7B                  | $20.9B            | $242.2B     | +7.1%          | $55.7B           | 23.0%            | $16.4B               | 6.8%          | $13.8B         | +15.0%              | 5.7%           | $15.0B             | 6.2%           | $2.5B                    | \~$2.5B          | $11.3B               | 4.7%          | \~$68B                | 12%      | \~14%    | 23.5%   | 7.1%    | 6.5%                | 0.9               | 0.69            | 0.69            | \~4%              |
| **2020** | $356.0           | $66.8                | 21.7×   | 5.3×    | $333B          | $201.5B          | $135.5B               | $66.0B                  | $23.8B            | $257.1B     | +6.2%          | $65.5B           | 25.5%            | $18.5B               | 7.2%          | $15.4B         | +11.6%              | 6.0%           | $20.1B             | 7.8%           | $2.6B                    | \~$2.6B          | $12.8B               | 5.0%          | \~$79B                | 13%      | \~15%    | 22.4%   | 7.9%    | 5.8%                | 0.9               | 0.61            | 0.67            | \~4%              |
| **2021** | $508.0           | $74.0                | 21.3×   | 6.9×    | $473B          | $212.2B          | $139.3B               | $72.9B                  | $25.0B            | $287.6B     | +11.9%         | $67.3B           | 23.4%            | $23.97B              | 8.3%          | $17.73B        | +14.8%              | 6.2%           | $19.9B             | 6.9%           | $3.0B                    | \~$3.0B          | $14.7B               | 5.1%          | \~$91B                | 12%      | 18%      | 25.2%   | 8.4%    | 6.9%                | 0.7               | 0.60            | 0.66            | \~5%              |
| **2022** | $532.0           | $86.7                | 17.8×   | 6.1×    | $495B          | $226.2B          | $144.3B               | $81.9B                  | $26.5B            | $324.2B     | +12.7%         | $79.6B           | 24.5%            | $28.44B              | 8.8%          | $20.12B        | +15.9%              | 6.2%           | $23.4B             | 7.2%           | $3.3B                    | \~$3.3B          | $16.8B               | 5.2%          | \~$105B               | 12%      | \~19%    | 27.2%   | 9.1%    | 7.4%                | 0.7               | 0.67            | 0.64            | \~4%              |
| **2023** | $527.0           | $94.5                | 22.1×   | 5.6×    | $487B          | $271.2B          | $169.0B               | $102.2B                 | $25.4B            | $371.6B     | +14.7%         | $90.96B          | 24.5%            | $32.36B              | 8.7%          | $22.38B        | +11.2%              | 6.0%           | $25.68B            | 6.9%           | $3.7B                    | \~$3.7B          | $18.4B               | 5.0%          | \~$113B               | 11%      | \~20%    | 27.0%   | 8.6%    | 10.0%               | 1.0               | 0.78            | 0.62            | 4.4%              |
| **2024** | $505.0           | $98.4                | 32.6×   | 5.1×    | $466B          | $290.1B          | $186.0B               | $104.1B                 | $28.8B            | $400.3B     | +7.7%          | $88.12B          | 22.0%            | $7.80B               | 1.9%          | $15.51B        | -30.7%              | 3.9%           | $24.2B             | 6.0%           | $4.0B                    | \~$4.0B          | $11.5B               | 2.9%          | \~$121B               | 12%      | \~?%     | 15.5%   | 5.3%    | 41.6%               | 0.8               | 0.76            | 0.64            | 4.5%              |

**Sources:** UnitedHealth SEC filings , Macrotrends , StockAnalysis , Yahoo Finance . (Note: 2024 net income was unusually low due to one-time charges ; adjusted 2024 EPS was \~$27.66 , which would make P/E \~18× adjusted.)

**Table Interpretation:** UnitedHealth exhibited consistent **growth** - revenue nearly tripled from $157B in 2015 to $400B in 2024, and net income roughly tripled (adjusted for 2024 one-offs). Margins were stable to rising until 2024's dip. Notably, **gross margin** expanded from \~23% in 2015 to \~25%+ by 2022, reflecting the higher mix of Optum services and perhaps improved pricing. **Operating margin** hovered in the 7-9% range most years, peaking at 8.8% in 2022 . **Return on equity** rose to upper-20%s by 2022-2023 , indicating very efficient use of capital (partly boosted by leverage and buybacks). **Debt-to-equity** trended down from \~0.95× in 2015 to \~0.76× in 2024, as equity grew faster than debt - showing a stronger balance sheet over time. The **current ratio** remained below 1 (typical for insurers with large current claim liabilities), e.g. \~0.8, since premiums are collected in advance of claims. **Free cash flow** consistently covered net income (often 100%+ of net, due to non-cash expenses and timing) - UHG generated reliable cash to fund dividends and buybacks .

Overall, the metrics reflect a decade of **profitable growth**: double-digit EPS increases, high returns, a stable medical cost ratio (around 81-83% most years ), and improving efficiency (operating cost ratio down to \~14%). The anomaly is 2024's GAAP earnings drop (net margin 3.9%) due to special charges (cyberattack and divestitures) - excluding those, underlying 2024 net margin was \~6.9%. The long-term trend remains upward. These figures will inform the Buffett-style checklist and the valuation analysis that follow.

## **Buffett‑Style Checklist**

Legendary investor Warren Buffett has criteria for what he considers a **great company at a reasonable price**. Below we evaluate UnitedHealth Group against several Buffett-style standards:

### **1.**

### **Valuation Discipline:**

-   **P/E ≤ 15 (vs history):** UnitedHealth's trailing P/E has mostly ranged from \~17-22× in recent years, above the ≤15 benchmark. At the 2025 low, the forward P/E did briefly drop to \~12-14 , meeting this criterion. However, on a normalized basis, UNH typically trades higher. For example, in 2022 it was \~18×, in 2023 \~22× . *Verdict:* **Usually Fails.** Only during rare dips (like mid-2025) does UNH hit a P/E \~15 or below, otherwise it's priced at a premium for its quality. Buffett did buy in 2025 likely because it finally hit \~14× forward (a value range) , but historically it wouldn't qualify as "cheap" by this yardstick.

-   **P/B ≤ 1.5:** UNH's price-to-book has been far above 1.5 for the past decade, reflecting its high ROE business. It ranged \~3-7× (e.g. 2023 P/B \~5.6, even 2015 was \~3.3) in the table above. *Verdict:* **Fails.** A low P/B is not meaningful for an insurer with high intangibles and high ROE. Buffett often ignores P/B for such cases, focusing on earnings instead. On earnings, UNH's higher P/E has been somewhat justified by its \~20% ROE , but strictly on P/B, it doesn't meet ≤1.5 at all.

-   **Margin of Safety (25% below intrinsic):** This is subjective, but we can attempt to assess whether UNH offers a margin of safety. In mid-2025 when shares were \~$240-$300, our DCF (below) suggests intrinsic values considerably higher ($400+ even in conservative case). So at those levels, yes, it traded \~25%+ below intrinsic value (hence Buffett and others buying) . At the current $370, UNH is closer to (though still somewhat below) our estimated intrinsic value ($450 in nominal scenario). So right now it might have a small margin of safety, but not a full 25%. Historically, UNH seldom traded at a deep discount - except briefly in market panics (2009, 2020 pandemic crash, 2025 healthcare selloff). *Verdict:* **Borderline/Partial Pass.** When bought opportunistically, UNH can meet a 25% MOS (as in 2025). At typical prices, it tends to reflect its value fairly well (not often deeply undervalued).

### **2.**

### **Cash Generation & Allocation:**

-   **Positive FCF each year; FCF/Revenue > 5%:** UnitedHealth has generated positive free cash flow every year for decades . Even in heavy investment years or recessions, its FCF stayed robust. For instance, 2020 FCF was \~$20.1B , 2021 \~$19.9B , 2022 $23.4B , 2023 $25.7B . All positive and growing. **FCF margin** averaged \~6-7% of revenue (see table: generally above 5%). In 2024, FCF was \~$24.2B on $400B rev , \~6%. *Verdict:* **Pass.** UNH is a cash machine, consistently converting \~90-100% of earnings to free cash and maintaining FCF/Revenue well above 5%. Buffett loves strong cash generators, and UNH fits the bill.

-   **Return on Retained Earnings ≥ 12%:** This Buffett measure examines how well the company reinvests earnings. One approach: look at cumulative retained earnings vs. gain in net income over a period. From 2013 to 2023, UNH's retained earnings grew by \~$80B (from \~$31B to $113B), while annual net income grew by \~$12B (from $5.5B to $17.5B) . The "return" on that retention would be \~$12B/80B = 15% (though this is a simplistic calc). Another method: average ROE and payout ratio. UHG's ROE \~20-25% and it retains \~70% of earnings after dividends, so one would expect \~14-18% return on retained capital, which checks out with actual growth. Indeed, EPS rose from $5.50 in 2013 to \~$24 (adj.) in 2023, a CAGR of \~15%, roughly matching the internal returns. *Verdict:* **Pass.** UnitedHealth has demonstrated that its reinvested earnings yield well above 12% in additional earnings - a sign of effective use of capital (via acquisitions, expansion, buybacks).

### **3.**

### **Growth & Predictability:**

-   **EPS Record - Positive & rising each year for 10 yrs:** UnitedHealth's **GAAP EPS** has been positive each year and generally rising, but *not strictly every single year without fail*. From 2013 ($5.50) to 2022 ($21.18) it rose consistently . 2024 was an outlier: GAAP EPS dropped to $15.51 due to one-off charges . However, **adjusted EPS**actually grew in 2024 ($27.66 vs $27.20 in 2023 adj.) . If one smooths out extraordinary items, EPS grew every year. Buffett typically allows for one-time issues, focusing on underlying trend. From that view, UNH's EPS trajectory is robustly upward. Only *GAAP*-strictly, 2024 broke the streak. *Verdict:* **Mostly Pass.** Barring unusual charges, UNH grew EPS every year for over a decade. It fails the absolute letter (due to 2024 GAAP dip), but passes the spirit of consistent earnings growth.

-   **Book Value per Share 10-yr CAGR ≥ 10%, no year of decline:** UHG's **book value/share** grew from \~$24 in 2012 to \~$98 in 2024 (excluding 2024 unrealized losses effect) - approximately a 12-13% CAGR. There were *no declines in reported equity year-to-year* in the last 10 years; it rose each year (helped by retained profits). However, on a per-share basis, if share count is reduced, BVPS can dip if buybacks > earnings. In 2018, for instance, heavy buybacks plus AOCI changes made BVPS flat. But generally, BVPS marched upward: $35 in 2015 to $94.5 in 2023 . CAGR \~11%. No single year saw a contraction in total equity or BVPS in the past decade (even in 2024, equity still increased slightly). *Verdict:* **Pass.** UnitedHealth's book value/share compounded above 10% with remarkable consistency, satisfying Buffett's book growth criterion.

-   **Owner's Earnings positive every year, OE/Market Cap ≥ 10%:** "Owner's earnings" is Buffett's term akin to FCF available to shareholders (net income + dep/amort - capex). UNH's owner earnings are positive each year (given positive FCF and stable working capital). The **OE/Market Cap** threshold (≥10%) is a high bar - essentially an earnings yield of 10%. At the 2025 low, UNH's OE/Market Cap did cross \~10% (FCF \~$26B vs market cap \~$270B = \~9.6%, nearly there, and if using 2025 depressed market cap \~$330B and FCF $29B projected = \~8.8%). For most of the decade, UNH traded with an earnings yield \~4-6% (market cap grew in line with earnings, keeping yield modest). Only in crises has its yield approached 10%. *Verdict:* **Fails in normal times.** Under typical pricing, UNH's owner earnings yield is well below 10%. However, in mid-2025 the stock became sufficiently cheap that it was close to passing this (hence attractive to value buyers). Buffett's standard is very stringent - few mega-caps aside from deep-value cases have an earnings yield >10%. UHG usually doesn't, due to its premium valuation for growth and stability.

### **4.**

### **Balance-Sheet Safety:**

-   **Debt-to-Equity < 0.5:** UnitedHealth's debt/equity was **above 0.5** for the entire decade. It hovered \~0.7-0.9 most years (e.g. 2023 D/E \~0.78) and only by Q3 2025 did it reach \~0.79 (still >0.5) . While high, note that a lot of UHG's "debt" is financing for its capital-intensive working capital (short-term borrowings, etc.). The company has significant goodwill from acquisitions, lowering the equity base, so D/E looks high. But interest coverage is strong (see next). Nonetheless, strictly <0.5 criterion is not met. *Verdict:* **Fail.** UNH uses more leverage than Buffett's ideal. That said, it's not overleveraged relative to cash flow - debt is \~2× EBITDA, which is safe for its business, but the ratio >0.5 means it misses this screen.

-   **Interest Coverage ≥ 3×:** UHG's **EBIT/interest** is very comfortable. In 2023, EBIT was $32.36B vs interest $3.25B , coverage \~10×. Even in 2015, EBIT $11B vs interest $0.79B , coverage \~14×. It has always been well above 3×. *Verdict:* **Pass.** Plenty of cushion to cover interest payments - UnitedHealth could endure sizable earnings drops and still meet interest easily (in 2024, interest coverage dipped to \~2.4× on GAAP EBIT due to one-time charge, but on normalized earnings it's still >10×). Normally, this criterion is easily satisfied.

-   **Interest Exp. / Op. Income ≤ 15%:** This is essentially the inverse of coverage \~6.7×. UHG's interest expense has been around 5-10% of operating income historically. For example, 2016 interest $1.067B was 8.3% of $12.93B op income ; 2023 interest $3.25B was 10% of $32.36B op income . All years in our table are under 15% except 2024 (where one-offs shrank op profit, interest was \~41% of the much-reduced $7.8B op profit, failing that year). But adjusting for charges, 2024 would also be under 15%. *Verdict:* **Pass (excluding unusual charge year).**UnitedHealth generally keeps interest <10% of operating earnings, indicating prudent leverage.

-   **Current Ratio > 1.5:** UHG's current ratio is <1 (0.8-0.9) throughout, which is typical for an insurance firm (they receive premiums upfront as current liabilities, and invest the cash in long-term assets). So by conventional measure it fails, but this is not a concern given the nature of the business (regulators ensure reserves). Still, Buffett's checklist item would flag it. *Verdict:* **Fail (on paper).** However, insurers operate differently - more relevant is regulator RBC (risk-based capital) which UHG's subsidiaries maintain above required levels . But purely on current assets vs liabilities, it doesn't meet >1.5.

### **5.**

### **Profitability & Efficiency:**

-   **Gross Margin ≳ 40%:** UnitedHealth's gross margin is far lower - \~22-25% in recent years . It will likely never approach 40% given the insurance model (passing through 80%+ of premiums as medical costs). Buffett's 40% gross margin is aimed at product companies with pricing power. UNH fails this big time. Yet, its \~25% gross margin on $400B revenue is still huge in absolute dollars ($90B gross profit) . *Verdict:* **Fail.** The model inherently has high cost of revenue. But that doesn't preclude it from being a great business - it just runs on volume and efficiency rather than high mark-up per unit.

-   **Net Profit Margin ≳ 20%:** Similarly, UNH's net margin \~5-6% is nowhere near 20% . This criterion suits businesses like software or consumer goods, not health insurance. UHG's stable 5-6% net margin is actually excellent for its industry (peers like Anthem or Cigna have \~4-6%). But strictly, it fails the 20% bogey. *Verdict:***Fail.**

-   **ROE ≥ 15% (10-yr avg):** UnitedHealth's average ROE over 2015-2024 is \~20% (ranged \~17-27% annually) . That's well above 15%. Even when equity grew, ROE remained strong (helped by some leverage). *Verdict:* **Pass.**High ROE consistently indicates an effective business model. Buffett likes companies with sustained high ROE, and UNH certainly qualifies.

-   **ROIC ≥ 12% (10-yr avg):** Return on invested capital (which considers debt + equity) for UNH is a bit lower than ROE due to leverage, but likely still in the low-to-mid teens. In 2023, for instance, NOPAT \~ $26B (EBIT $29.1B less 21% tax) on (debt+equity \~$205B) yields \~12.7% ROIC. Historically it might have been 10-12%. Given Optum's high returns and effective use of capital, UNH probably averages around 12%. *Verdict:* **Near Pass.** It should be around the threshold. If we calculate over a decade, yes likely \~12-15%. The consistency of profit growth suggests efficient reinvestment. This is evidenced by doubling of net income on a less-than-doubling of capital base. So I would lean Pass - it's not a capital intensive low-return enterprise; it earns solid returns on incremental capital.

-   **ROA ≥ 6%:** Net income to total assets was \~5.2% in 2015, rising to \~8.4% in 2021, then back to \~5.3% in 2024 (due to that earnings dip) - typically around 6-7% in normal years . In 2022, ROA = $20.1B/$226B = 8.9%. Over 10 years, average ROA \~6-7%. So it mostly meets ≥6%. *Verdict:* **Pass.** UnitedHealth's efficient use of assets (especially float investment) yields ROA at or above 6% in most years, which is impressive given insurance companies often have lots of assets/investments.

-   **Depreciation / Gross Profit ≤ 10%:** In 2023, depreciation & amortization was $3.97B on gross profit $90.96B , which is \~4.4%. Historically also low single-digit. UNH isn't very capital intensive; much of its "capital" is goodwill from acquisitions. D&A as % gross profit ranged \~5-8% over the decade (it was a bit higher when Optum was smaller, e.g. 2015 D&A \~$2B vs gross profit \~$37B = \~5.4%). Always under 10%. *Verdict:* **Pass.** Depreciation is a small fraction of gross profit, indicating low capital requirements relative to its earnings power - a trait Buffett likes (business doesn't need heavy capex to maintain operations).

### **Buffett Checklist Summary:**

UnitedHealth scores well on **quality measures**: high ROE, high ROIC, consistent growth, strong cash generation, decent returns on retained earnings, and not overburdened by interest. It falls short on **"Buffett bargain" metrics**: it usually isn't cheap (P/E, P/B, margin of safety) and its margins are thin in percentage terms (inherent to insurance). Buffett has historically preferred simpler businesses with high margins, but he also appreciates exceptional insurers (he owns GEICO and others). In fact, Berkshire's recent purchase of UNH stock in 2025 implies he sees enough greatness to override some checklist misses.

So, does UNH meet Buffett's definition of a great company at a fair price? **Business-wise, yes:** it has durable competitive advantages, predictable earnings (aside from one-offs), and uses capital effectively - hallmarks of a Buffett-type company. **Valuation-wise, not usually:** until its 2025 drop, UNH seldom traded at the deep discount Buffett ideally wants. In mid-2025 it briefly did, which likely prompted Berkshire's buy .

In detail:

-   Valuation: *Mostly Fail* (but can pass temporarily in market dips).

-   Cash generation: *Pass.*

-   Retained earnings return: *Pass.*

-   Earnings/book growth: *Pass (with minor caveat in 2024 GAAP).*

-   Balance sheet: *Mixed* (debt higher than Buffett ideal, but interest coverage strong).

-   Profitability: *Mixed* (ROE/ROIC great, but low margins percent-wise, albeit normal for sector).

**Overall:** UnitedHealth might not fit a traditional Buffett stock profile like Coca-Cola, but it shares many qualities of Buffett's favorite businesses (high return on capital, long-term growth runway, excellent management). Given Buffett's own investment in it, one could conclude *UnitedHealth meets the spirit of the Buffett criteria*, if not all the letter.

## **Intrinsic Valuation - Discounted Cash Flow (DCF) Analysis**

We conduct a **Discounted Cash Flow analysis** for UnitedHealth Group under three scenarios - **Conservative**, **Nominal (Base)**, and **Optimistic** - to estimate the stock's intrinsic value. All figures are in USD. We will project 10 years of free cash flows, then use a terminal value, and discount at a 10% rate (a standard equity hurdle rate for Buffett-style analysis).

**Baseline Inputs:** UHG's *free cash flow* in 2023 was about **$25.7 billion** . The company's *free cash flow growth* has varied: over the past decade, FCF grew \~13-15% annually on average, but with some slower years and some faster (e.g. +22.8% in 2020, -1.2% in 2021) . We will use **FCF = $25.7B for year 0 (2024)** as our starting point.

We also assume **910 million shares outstanding** (approx Q4 2025 after buybacks) for per-share values, and a long-term **terminal growth of 2.5%** (roughly GDP growth) for base case. Margin of safety threshold is 25% below intrinsic.

### **Conservative Case**

###  **-**

### **Minimal Growth**

**Assumption:** Use the **lowest FCF growth rate observed** in the past 10 years as the future growth. The worst was a slight decline: -1.16% from 2020 to 2021 (essentially flat). We will be a tad conservative and assume **0% FCF growth** (flat free cash flow) for the next 10 years. This simulates a scenario where UnitedHealth's FCF stagnates (perhaps due to sustained high medical costs or regulatory constraints). Terminal growth beyond year 10 we set at a modest **1%** (just to account for inflation below GDP, reflecting a very low-growth future).

**DCF Calculation:**

-   Years 1-10: FCF remains $25.7B each year (no growth).

-   Terminal Value at end of Year 10: FCF in Year 11 = $25.7B \* (1.0 growth) = $25.96B. Terminal value = $25.96B / (10% - 1%) = \~$288.5B.

-   Present Value of FCF Years 1-10: Since it's an annuity of 25.7B for 10 years, PV = 25.7B \* \[(1 - (1+0.10)^-10)/0.10\] = 25.7B \* 6.1445 = \~$158.9B.

-   Present Value of Terminal: $288.5B / (1.10^10) = $288.5B / 2.593 = \~$111.2B.

-   **Total PV = $158.9B + $111.2B = $270.1B.**

-   Intrinsic Equity Value = $270.1B (we assumed no debt separately since we used FCF to firm and WACC \~10%; to be precise, UHG has net debt \~$40B, but using equity discount 10% approximates equity value directly given stable debt).

-   Per Share Value = $270.1B / 910M = **$296 per share**.

The conservative DCF suggests intrinsic value around **$296/share**. At the current \~$370, the stock is *above* this conservative value - implying no margin of safety if zero growth indeed materialized. A 25% margin of safety off $296 would mean a "buy" price of **$222** or lower. In mid-2025 the stock did hit \~$240 (close to that MOS range), but today's price is higher. This scenario is quite pessimistic - essentially assuming UnitedHealth never grows FCF again. Given healthcare demand and UHG's history, zero growth is possible only under very adverse conditions (like heavy regulation capping profits).

### **Nominal Case**

###  **-**

### **Average Historical Growth**

**Assumption:** Use the **average FCF growth** of the past decade as the future growth. From 2013-2023, FCF grew roughly 12-15% annually (we saw EPS around 15%, FCF a bit lumpy but median growth \~9.7% for 2020-24 and higher earlier). To be slightly cautious, we'll use **10% annual FCF growth** for the first 5 years, then taper to 5% for the next 5 years (to reflect a slowing as the company gets larger). This averages out to \~7-8% over 10 years, a bit lower than historical, acknowledging the law of large numbers. Terminal growth after year 10 set at **2.5%** (approx inflation/GDP growth), reflecting a mature state by then.

**DCF Calculation:**

-   Years 1-5: FCF grows 10%/yr from $25.7B. So Year 5 FCF = $25.7B \* (1.10)^5 = $25.7B \* 1.6105 = $41.4B.

-   Years 6-10: FCF grows 5%/yr from $41.4B in Year 5. Year 10 FCF = $41.4B \* (1.05)^5 = $41.4B \* 1.2763 = $52.8B.

-   Terminal Value at end of Year 10: Year 11 FCF = $52.8B \* 1.025 = $54.1B. TV = $54.1B / (10% - 2.5%) = $54.1B / 7.5% = $721.3B.

-   Present value calculations (discount 10%):
    > *PV of Years 1-5:* We discount each year or use formula. For precision:
    > Year1: 28.27B /1.1 = 25.7B (coincidentally the same as starting FCF because 10% growth then 10% discount offset).
    > Year2: 31.10B /1.1^2 = 25.7B (by design, all 5 years will PV to same 25.7B if growth=discount for that period). So sum of Years1-5 PV = 5 \* 25.7B = $128.5B.
    > *PV of Years 6-10:* Need to discount these: FCF Year6 = $43.5B (Year5 41.4B \*1.05), to Year10 = $52.8B as stated. We can sum or take it as growing annuity. For simplicity, we'll compute individually:
    > Year6 PV: 43.5B /1.1^6 = 43.5/1.7716 = 24.55B.
    > Year7 PV: 45.7B /1.1^7 = 45.7/1.9487 = 23.46B.
    > Year8 PV: 48.0B /1.1^8 = 48.0/2.1436 = 22.40B.
    > Year9 PV: 50.4B /1.1^9 = 50.4/2.3579 = 21.37B.
    > Year10 PV: 52.8B /1.1^10 = 52.8/2.593 = 20.36B.
    > Sum PV Years6-10 = $112.1B.
    > *PV of Terminal:* $721.3B / (2.593) = $278.0B.

-   **Total PV = $128.5B + $112.1B + $278.0B = $518.6B.**

-   Equity Value ≈ $519B; Per Share = $519B / 910M = **$570 per share**.

The base case DCF yields about **$570/share intrinsic value**. This suggests the stock is undervalued at current \~$370 (trading at 65% of intrinsic). The margin of safety (25% below $570) would be **$428**. The current price $370 is below that by about 14% - a moderate margin of safety. This implies that, if UNH indeed can average high-single-digit FCF growth (which is plausible given past performance), it's an attractive buy. Notably, $570 is close to the stock's all-time high ($550 in late 2021) - indicating the market did price in that optimism then. Now, after the 2025 selloff, the stock is \~35% off its highs, providing potential upside if our nominal case plays out.

### **Optimistic Case**

###  **-**

### **Rebound to Best Growth**

**Assumption:** Use the **highest FCF growth rate observed** historically for future projections. The best one-year growth was +22.8% (2020) . That was extraordinary (due to suppressed 2019 spending and efficient operations during COVID). For a sustained optimistic scenario, we might assume **15% annual FCF growth** for the next 5 years (somewhat less than 22%, but close to UNH's best multi-year stretch which was \~15% CAGR), then 10% for the following 5 years (if everything goes right, it maintains double-digit growth longer). Terminal growth we set at **3%**, assuming the company still grows slightly above inflation beyond 10 years due to some remaining market expansion or efficiency.

This scenario could be justified if, say, UnitedHealth launches new businesses or dramatically lowers costs with technology, allowing margins to expand and revenue to continue double-digit growth (similar to its 2010-2020 trajectory, possibly further boosted by acquisitions).

**DCF Calculation:**

-   Years 1-5: 15% growth from $25.7B. Year5 FCF = 25.7 \* (1.15)^5 = 25.7 \* 2.011 = $51.7B.

-   Years 6-10: 10% growth from $51.7B. Year10 FCF = 51.7 \* (1.10)^5 = 51.7 \* 1.611 = $83.3B.

-   Terminal Value at end of Year 10: Year11 FCF = $83.3 \* 1.03 = $85.8B. TV = 85.8 / (10% - 3%) = 85.8/0.07 = $1,225.7B.

-   Present values:
    > *Years 1-5:* Under 15% growth vs 10% discount, present value factor = (1.15/1.10) for each year's growth-a bit complex to do directly, easier to sum year by year:
    > Year1 FCF: 29.56B; PV = 29.56/1.1 = 26.87B.
    > Year2: 34.00B; PV = 34.00/1.21 = 28.10B.
    > Year3: 39.10B; PV = 39.10/1.331 = 29.39B.
    > Year4: 44.97B; PV = 44.97/1.464 = 30.73B.
    > Year5: 51.72B; PV = 51.72/1.611 = 32.10B.
    > Sum PV Y1-5 = $147.2B.
    > *Years 6-10:* Using 10% growth, 10% discount, interestingly that's same as first case for that span (growth=discount => each year's PV roughly equal). But since Year5 ended higher, let's do individually:
    > Year6: 56.89B; PV=56.89/1.772 = 32.11B.
    > Year7: 62.58B; PV=62.58/1.949 = 32.13B.
    > Year8: 68.83B; PV=68.83/2.144 = 32.11B.
    > Year9: 75.71B; PV=75.71/2.359 = 32.09B.
    > Year10:83.28B; PV=83.28/2.593 = 32.12B. (We see a pattern: roughly $32.1B each, since growth=discount for that stage).
    > Sum PV Y6-10 = $160.6B.
    > *Terminal:* $1,225.7B / 2.593 = $472.7B.

-   **Total PV = $147.2B + $160.6B + $472.7B = $780.5B.**

-   Per Share = $780.5B / 910M = **$857 per share**.

The optimistic scenario yields an intrinsic value of **\~$850+ per share**. This is more than double the current price - implying huge upside if UNH can recapture its peak growth momentum and maintain it. A 25% MOS on that would be **$643**, far above today's price. However, this scenario is arguably aggressive; sustaining 15% then 10% growth for 10 years on such a large base might be challenging without transformative changes or big market expansions (though not impossible given healthcare's large addressable market and UHG's track record).

For context, $857 is likely an upper bound - that would make UHG one of the most valuable companies globally (market cap \~$780B). It isn't inconceivable long-term (healthcare is \~18% of US GDP, and UHG could grab more share or expand globally or into new sectors). But investors should apply probability - the optimistic case might have, say, a 25% chance; the base case perhaps 50%; the conservative maybe 25%. Weighted, the expected intrinsic might be closer to \~$570-$600.

**DCF Summary:**

-   **Conservative (0% growth):** ≈ **$296/share** intrinsic. *No* margin of safety at current price ($370 > $296). Implies downside risk if UHG stagnates.

-   **Base (avg \~8% growth):** ≈ **$570/share** intrinsic. Current price \~$370 is about 35% below this, offering a margin of safety (370 is \~65% of $570, which is >25% discount). So stock appears undervalued if UHG grows at a reasonable pace.

-   **Optimistic (robust growth):** ≈ **$857/share** intrinsic. Current price is less than half of this - huge upside if UHG truly fires on all cylinders for a decade.

**Buy Price with 25% MOS:** We take the intrinsic value and multiply by 0.75.

-   Conservative IV $296 → MOS buy price \~$222.

-   Base IV $570 → MOS buy price \~$428.

-   Optimistic IV $857 → MOS buy price \~$643.

Thus, if one were extremely conservative, they'd only buy under \~$222 (which happened briefly around 2011 last, not realistic now). More reasonably, at \~$370 the stock appears to meet a margin of safety relative to base-case (\~65% of IV, i.e. 35% discount). It's below the MOS threshold of $428, albeit not by a huge margin - it suggests **there is a margin of safety, but not super wide**. However, given UHG's stability, one might accept a slightly smaller MOS.

**Step-by-Step Explanation:** We projected cash flows based on growth scenarios drawn from UNH's history: the **minimum growth** (assuming almost no improvement), the **average trend**, and the **best trend**. We then discounted those at 10% to present values and divided by share count. This captures the value of UnitedHealth's future cash earning power in today's dollars.

Notably, the key driver is **growth assumptions**: small changes there swing value a lot. Also, the **terminal value** (value beyond year 10) contributed around 50-60% of total value in our base case, as is common for a stable growth company. This means long-term growth matters. If one believes UnitedHealth can continue \~10% growth even beyond 10 years, then the optimistic scenario becomes more likely, raising intrinsic value further.

In Buffett's style, one might also cross-check via **earnings yield** vs **required return**. At $370, UNH's forward earnings (2024 adj. \~$27) yield \~7.3%. That's higher than bonds, but below Buffett's 10% target return; however, if earnings grow \~10% annually, the investor's return would be \~17%/yr (7% yield + 10% growth), which is excellent. Our DCF essentially captured that math in the base scenario.

In conclusion, **UnitedHealth appears undervalued in the base and optimistic scenarios**, suggesting a potential investment opportunity for long-term investors. The conservative case is quite bleak and likely too pessimistic given UHG's past, but it provides a floor - even in a zero-growth future, the DCF value \~$300 means the current price isn't wildly above a worst-case value. Thus, downside seems limited, while upside potential is significant, aligning with Buffett's margin of safety principle in the base/optimistic cases.

*(All amounts in USD; assumptions based on publicly available financial data . These valuations are estimates and not guarantees.)*

## **Financial Research Key Insights**

*(All financial figures are in U.S. dollars. Past performance is no guarantee of future results. These insights are based on historical data and are not predictions.)*

-   **UnitedHealth's Growth Resilience:** Over the past decade, UnitedHealth compounded revenue \~12% annually and EPS \~15% annually . Even accounting for the one-time profit dip in 2024, underlying earnings growth remained intact. This consistent growth, coupled with high returns on equity (\~20%+), underscores UnitedHealth's status as a compounding machine. It has achieved this via a balanced strategy of expanding membership (top-line) and improving efficiency (stable medical cost ratios, lower admin ratio), plus strategic acquisitions fueling Optum's rise .

-   **Robust Free Cash Flow & Shareholder Returns:** UnitedHealth converts a high portion of earnings to free cash flow - often over 100% of net income in cash flow from operations . In 2020-2023, annual FCF ranged $20-26B and covered dividends \~4x over. The company put this cash to work via rising dividends (10-year DPS CAGR \~20%) and substantial share buybacks (about $5-10B/year in recent years) . Over 2015-2024, share count fell \~9% (from \~954M to \~920M), enhancing EPS growth. This disciplined capital return policy has rewarded shareholders and signals management's confidence in the business (especially noteworthy are opportunistic buybacks during price dips and CEO Hemsley's personal stock purchases in 2025 ).

-   **Healthy Financial Position:** Despite growth and acquisitions, UnitedHealth maintained a strong balance sheet. Debt increased with deals (total debt \~$79B in 2025), but leverage ratios remain comfortable (net debt/EBITDA ≈ 1.5×, interest coverage \~10×) . The debt-to-capital ratio \~44% is reasonable for an insurer with stable cash flows . Importantly, the company's liquidity is solid: \~$28B in cash and investments on hand and significant short-term investments backing insurance reserves. Regulatory capital levels in its insurance subsidiaries are well above requirements (no red flags on reserve adequacy have arisen). This financial strength allows UHG to invest through cycles and seize acquisition opportunities without jeopardizing stability.

-   **Valuation Appears Reasonable:** At \~$370/share (Oct 2025), UNH trades around 14.5× forward 2025 earnings (using management's $16.25+ adj. EPS guidance ) and \~11× EV/EBITDA. This is near the low end of its historical valuation range. Our DCF analysis indicates an intrinsic value of \~$570 in a base case, suggesting the stock is \~35% undervalued. Key multiples also support this: the forward earnings yield \~7% plus expected growth \~10% implies a potential \~17% annual total return - attractive relative to the market. The PEG ratio (P/E divided by growth) is \~1.0, indicating a fair or cheap valuation for its growth profile. Additionally, UNH's dividend yield \~1.6% is modest but the dividend is highly secure (payout \~30%) and growing fast (raised 14% in 2023). Given UnitedHealth's dominant franchise and consistent execution, the current valuation offers a margin of safety for long-term investors (barring any major regulatory shock).

-   **Buffett Criteria Mostly Met:** When benchmarked against Buffett's checkpoints, UnitedHealth scores well on quality and moat factors (high ROE, consistent growth, strong cash generation, honest and capable management) . It falls short on some strict value metrics (often trading above 15× earnings and with slim margins in percentage terms, inherent to its industry). However, Buffett's own investment via Berkshire in 2025 indicates he sees it as a great company at a *good enough* price . Indeed, UnitedHealth's economics - converting revenue to steady profits and high returns on retained earnings - are precisely the type he favors. Thus, for investors seeking a Buffett-style investment, UNH offers the rare combo of a wide moat business and a currently reasonable price.

In sum, **UnitedHealth Group stands out as a high-quality, cash-rich franchise that is delivering growth and shareholder value, and its stock - after the 2025 correction - provides a potentially attractive entry point for long-term investors.**

*Financial Disclaimer: This analysis is for informational purposes and not an investment recommendation. All data cited are from reliable public sources including UnitedHealth's SEC filings and investor materials. Future results could differ from past performance discussed. Investors should conduct their own due diligence and consider their financial advisors' guidance before making investment decisions.*